Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Wei, Huafeng ^a,c   Zhao, Likun ^b   Li, Wei ^a,c   Fan, Kexing ^a,c   Qian, Weizhu ^a,c   Hou, Sheng ^a,c   Wang, Hao ^a,c   Dai, Min ^d   Hellstrom, Ingegerd ^d   Hellstrom, Karl Erik ^d   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^c LIAOCHENG UNIVERSITY   (China)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CISPLATIN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY PD 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; FEMALE; IMMUNOLOGICAL MEMORY; LONG TERM SURVIVAL; LUNG CANCER; LYMPHOCYTOPOIESIS; MOUSE; MOUSE MODEL; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; SURVIVAL TIME; TUMOR MODEL; TUMOR REGRESSION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD137; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INJECTIONS, INTRAPERITONEAL; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84893199565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084927     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166. PubMed: 23335087.
2. Leary A, Pautier P, Tazi Y, Morice P, Duvillard P et al. (2012) The molecular biology of epithelial ovarian cancer. Bull Cancer 99: 1161-1173. PubMed: 23238064.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200. doi:10.1200/JCO.2003.02.153. PubMed: 12860964. (Pubitemid 46606249)
4. Ali AY, Farrand L, Kim JY, Byun S, Suh JY et al. (2012) Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci 1271: 58-67. doi:10.1111/j.1749-6632.2012.06734.x. PubMed: 23050965.
5. Kandalaft LE, Powell DJ Jr., Singh N, Coukos G (2011) Immunotherapy for ovarian cancer: what's next? J Clin Oncol 29: 925-933. doi:10.1200/JCO.2009.27. 2369. PubMed: 21079136.
6. Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE et al. (2003) Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 15: 751-763. doi:10.1093/intimm/dxg074. PubMed: 12750359. (Pubitemid 36675806)
7. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ et al. (2001) Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 51: 254-261. doi:10.1159/000058060. PubMed: 11408737. (Pubitemid 32620125)
8. Schöndorf T, Engel H, Kurbacher CM, Brenne U, Kolhagen H et al. (1998) Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients. J Soc Gynecol Investig 5: 102-107. doi:10.1016/S1071-5576(97)86333-2. PubMed: 9509389. (Pubitemid 28099769)
9. Wei H, Liu P, Swisher E, Yip YY, Tse JH et al. (2012) Silencing of the TGF-beta1 gene increases the immunogenicity of cells from human ovarian carcinoma. J Immunother 35: 267-275. doi:10.1097/CJI.0b013e31824d72ee. PubMed: 22421944.
10. Vermeij R, Leffers N, Melief CJ, Daemen T, Nijman HW (2012) Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des 18: 3804-3811. doi:10.2174/138161212802002805. PubMed: 22591425.
11. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213. doi:10.1056/NEJMoa020177. PubMed: 12529460. (Pubitemid 36077915)
12. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A et al. (2009) Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 119: 2231-2244. PubMed: 19620771.
13. Mantia-Smaldone GM, Corr B, Chu CS (2012) Immunotherapy in ovarian cancer. Hum Vaccin Immunother 8: 1179-1191. doi:10.4161/hv.20738. PubMed: 22906947.
14. Graziani G, Tentori L, Navarra P (2012) Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res 65: 9-22. doi:10.1016/j.phrs.2011.09.002. PubMed: 21930211.
15. McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L et al. (2008) Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 118: 376-386. doi:10.1172/JCI33365. PubMed: 18060045.
16. Yang Y, Yang S, Ye Z, Jaffar J, Zhou Y et al. (2007) Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res 67: 2339-2344. doi:10.1158/0008-5472.CAN-06-3593. PubMed: 17332366. (Pubitemid 46424255)
17. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I (2010) Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 37: 508-516. doi:10.1053/j.seminoncol.2010.09.008. PubMed: 21074066.
18. Pardoll D, Drake C (2012) Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 209: 201-209. doi:10.1084/jem.20112275. PubMed: 22330682.
19. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800. PubMed: 12091876.
20. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99: 12293-12297. doi:10.1073/pnas.192461099. PubMed: 12218188.
21. Xiao H, Huang B, Yuan Y, Li D, Han LF et al. (2007) Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 13: 1823-1830. doi:10.1158/1078-0432. CCR-06-2154. PubMed: 17325342. (Pubitemid 46952952)
22. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465. doi:10.1056/NEJMoa1200694. PubMed: 22658128.
23. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454. doi:10.1056/NEJMoa1200690. PubMed: 22658127.
24. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM et al. (2013) Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19: 462-468. doi:10.1158/1078-0432.CCR- 12-2625. PubMed: 23169436.
25. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K et al. (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109: 651-659. doi:10.1172/JCI14184. PubMed: 11877473. (Pubitemid 34204844)
26. Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A et al. (2012) Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 72: 3163-3174. doi:10.1158/0008-5472.CAN-12-0210. PubMed: 22570253.
27. Dai M, Wei H, Yip YY, Feng Q, He K et al. (2013) Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2. Inflammation - J Immunother 36: 248-257. doi:10.1097/CJI.0b013e3182943549.
28. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867. doi:10.1038/nature01322. PubMed: 12490959. (Pubitemid 36019639)
29. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545. doi:10.1016/S0140-6736(00)04046-0. PubMed: 11229684. (Pubitemid 32173595)
30. Feng Q, Wei H, Morihara J, Stern J, Yu M et al. (2012) Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol 127: 412-419. doi:10.1016/j.ygyno.2012.07.098. PubMed: 22828962.
31. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591. doi:10.1093/carcin/21.4.585. PubMed: 10753190. (Pubitemid 30214011)
32. Wei H, Wang H, Lu B, Li B, Hou S et al. (2008) Cancer immunotherapy using in vitro genetically modified targeted dendritic cells. Cancer Res 68: 3854-3862. doi:10.1158/0008-5472.CAN-07-6051. PubMed: 18483270.
33. Zhang H, Knutson KL, Hellstrom KE, Disis ML, Hellstrom I (2006) Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Mol Cancer Ther 5: 149-155. doi:10.1158/1535-7163.MCT-05- 0206. PubMed: 16432173.
34. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264. doi:10.1038/nrc3239. PubMed: 22437870.
35. Yao S, Zhu Y, Chen L (2013) Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 12: 130-146. doi:10.1038/nrd3877. PubMed: 23370250.
36. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK et al. (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187-2194. doi:10.1084/jem.20100643. PubMed: 20819927.
37. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF et al. (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207: 2175-2186. doi:10.1084/jem.20100637. PubMed: 20819923.
38. Kim YH, Choi BK, Kim KH, Kang SW, Kwon BS (2008) Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res 68: 7264-7269. doi:10.1158/0008- 5472.CAN-08-1365. PubMed: 18794112.
39. Li Q, Pan PY, Gu P, Xu D, Chen SH (2004) Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 64: 1130-1139. doi:10.1158/0008-5472.CAN-03-1715. PubMed: 14871848. (Pubitemid 38176920)
40. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L et al. (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186: 6905-6913. doi:10.4049/jimmunol.1100274. PubMed: 21551365.
41. Hall M, Gourley C, McNeish I, Ledermann J, Gore M et al. (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 108: 250-258. doi:10.1038/bjc.2012.541. PubMed: 23385789.
42. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLOS ONE 6: e19499. doi:10.1371/journal.pone.0019499. PubMed: 21559358.
43. Wei H, Hellström KE, Hellström I (2012) Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol 125: 727-733. doi:10.1016/j.ygyno.2012.03.018. PubMed: 22430613.
44. Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PDL1) in the treatment of advanced human cancer. Clin Cancer Res 19: 1021-1034. doi:10.1158/1078-0432.CCR-12-2063. PubMed: 23460533.